Can a Two-Drug punch before surgery beat ALK-Positive lung cancer?

NCT ID NCT07771764

NEW Not yet recruiting ⭐️ CURE ⭐️ Sponsor: First Affiliated Hospital of Fujian Medical University Source: ClinicalTrials.gov ↗

First seen Aug 18, 2026 · Last updated Aug 18, 2026

Summary

This trial is testing whether giving a combination of iruplaltinib and pemetrexed before surgery can shrink tumors in people with early-stage ALK-positive non-small cell lung cancer. The goal is to see if this pre-treatment improves the chance of removing all cancer during surgery and reduces the risk of it coming back. Participants receive the drugs for six weeks, then undergo surgery, followed by up to two years of iruplaltinib to help prevent recurrence.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: iruplaltinib combined with pemetrexed
What this could lead to: If successful, this approach could shrink tumors before surgery, potentially increasing the chance of complete removal and long-term remission in ALK-positive lung cancer.
What could go wrong: This is a small, early-phase study (30 patients) without a comparison group. The combination may cause side effects, and the benefit over standard care is unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALK-POSITIVE NON SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALK-POSITIVE NON SMALL CELL LUNG CANCER

Contacts and locations

Locations

Fuzhou Pulmonary Hospital

Fuzhou, Fujian, China
Fuzhou University Affiliated Provincial Hospital

Fuzhou, Fujian, China
The First Affiliated Hospital of Fujian Medical University

Fuzhou, Fujian, China
The Second Attached Hospital of Fujian Medical University

Quanzhou, Fujian, China
The Second Hospital of Longyan

Longyan, Fujian, China
Xiamen Medical College Affiliated Second Hospital

Xiamen, Fujian, China
Zhangzhou Hospital

Zhangzhou, Fujian, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.